Matthew J. Sikora

This study shows that CDH1 loss in human mammary epithelial cells remodels gene expression and lineage identity toward a luminal progenitor-like state, contributing to ILC oncogenesis.

This study shows that ER-positive ILC xenograft models replicate metastatic patterns and endocrine response of human invasive lobular breast carcinoma.

This paper integrates multiple transcriptomics assays to identify cancer biomarkers, finding GBP4 as a predictor of recurrence and immune remodeling.

This study investigates the predictability of progression-free survival in ovarian cancer using NanoString gene expression data from pre- and post-chemotherapy samples, finding low predictability and suggesting the need for larger datasets.

This study develops a metastatic ILC mouse model to study organ tropism, endocrine response, and bone remodeling in mILC.

This study identifies MDC1's role in ER co-regulation and DNA repair dysfunction in ILC, linking it to PARP inhibitor sensitivity.

This study investigates FGFR4's role in endocrine resistance in ER+ breast cancer and finds it does not generally mediate resistance, though HER2-like subtypes may respond to FGFR4 inhibition.

EstroGene2.0 is a multi-omic database that compiles data on estrogen receptor responses and resistance in breast cancer, revealing diverse transcriptomic changes and identifying key targets.

The paper examines glutamate-handling proteins in ILC and finds associations with tumor size, ER expression, and comorbidities, suggesting therapeutic targets.

The paper uses spatial data from ovarian cancer tumors to show that spatial organization of the immune microenvironment correlates with patient outcomes and can predict treatment response.

This study identifies Wnt signaling activation as a mechanism of PARP inhibitor resistance in HGSOC and shows that combining PARPi with Wnt inhibitors reduces tumor burden.